Skip to main content

Table 2 Cytological diagnosis for women screened after invitation and women undergoing routine or sporadic opportunistic testing

From: Impact of opportunistic testing in a systematic cervical cancer screening program: a nationwide registry study

Ā 

Screened after invitation1

Routine opportunistic testing2

Ā 

Sporadic opportunistic testing3

Ā 

nā€‰=ā€‰514,833 (71.2Ā %)

nā€‰=ā€‰149,778 (20.7Ā %)

Ā 

nā€‰=ā€‰58,590 (8.1Ā %)

Ā 

n

%

n

%

PPD % (95Ā % CI)4

PPR (95Ā % CI)5

n

%

PPD % (95Ā % CI)6

PPR (95Ā % CI)7

Cytological diagnosis

Normal cells

478,855

(93.0)

136,797

(91.3)

āˆ’1.7 (āˆ’1.87; āˆ’1.52)

0.98 (0.98;0.98)

53,866

(91.9)

āˆ’1.1 (āˆ’1.34; āˆ’0.86)

0.99 (0.99;0.99)

ASCUS

10,868

(2.1)

3,674

(2.5)

0.4 (āˆ’0.17; 0.95)

1.16 (1.12;1.21)

1,361

(2.3)

0.2 (āˆ’0.64;1.04)

1.10 (1.04;1.16)

ASC-H

2,175

(0.4)

846

(0.6)

0.2 (āˆ’0.38; 0.78)

1.34 (1.24;1.45)

250

(0.4)

0.0 (āˆ’0.83; 0.83)

1.01 (0.89;1.15)

AGC

634

(0.1)

236

(0.2)

0.1 (āˆ’0.52; 0.72)

1.28 (1.10;1.49)

99

(0.2)

0.1 (āˆ’0.81; 1.01)

1.37 (1.11;1.70)

LSIL

7,857

(1.5)

2,760

(1.8)

0.3 (āˆ’0.26; 0.86)

1.21 (1.16;1.26)

945

(1.6)

0.1 (āˆ’0.74; 0.94)

1.06 (0.99;1.13)

HSIL

4,791

(0.9)

2,228

(1.5)

0.6 (0.03; 1.17)

1.60 (1.52;1.68)

408

(0.7)

āˆ’0.2 (āˆ’1.05; 0.65)

0.75 (0.68;0.83)

Carcinoma in situā€‰+ā€‰AIS

106

(0.02)

45

(0.03)

0.01 (āˆ’0.56; 0.58)

1.46 (1.00;2.07)

14

(0.02)

0.0 (āˆ’0.79; 0.79)

1.16 (0.66;2.03)

Carcinoma8

42

(0.01)

42

(0.03)

0.02 (āˆ’0.58; 0.62)

3.44 (2.24;5.27)

2

(0.0)

āˆ’0.01 (āˆ’0.31; 0.29)

0.42 (0.10;1.72)

Inadequate cervical cytology9

9,109

(1.8)

2,988

(2.0)

0.2 (āˆ’0.37; 0.77)

1.13 (1.08;1.17)

1,538

(2.6)

0.8 (āˆ’0.04; 1.64)

1.48 (1.40;1.56)

Others10

29

(0.01)

8

(0.01)

0.0 (āˆ’0.78; 0.78)

0.95 (0.43;2.07)

1

(0.0)

NA

NA

  1. Numbers and proportion vary because of missing data.
  2. ASCUS: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL); AGC: atypical glandular cells; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; AIS: adenocarcinoma in situ. NA: Not available due to limited data;
  3. Statically significant results are shown in bold.
  4. 1) Cervical cytology obtained within 270Ā days after latest invitation.
  5. 2) Cervical cytology obtained between 271Ā days to 3Ā years after latest invitation or 2.5 to 3Ā years after latest cervical cytology.
  6. 3) Cervical cytology obtained less than 2.5Ā years after latest cervical cytology.
  7. 4) Prevalence proportion difference (%) for ā€œroutine opportunistic testingā€ compared to ā€œscreened after invitationā€.
  8. 5) Prevalence proportion ratio for ā€œroutine opportunistic testingā€ compared to ā€œscreened after invitationā€.
  9. 6) Prevalence proportion difference (%) for ā€œsporadic opportunistic testingā€ compared to ā€œscreened after invitationā€.
  10. 7) Prevalence proportion ratio for ā€œsporadic opportunistic testingā€ compared to ā€œscreened after invitationā€.
  11. 8) Carcinoma including squamous and carcinoma adenocarcinoma.
  12. 9) Not suitable for diagnosis
  13. 10) Necrosis